noscript

News and Announcements

Actinogen Medical US Roadshow Investor Presentation July 2016

  • Published July 15, 2016 12:03PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

15th July 2016, ASX Announcement

Focusing on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases

Xanamem™:  A prime investment opportunity 

  • Alzheimer’s – a significant unmet need in a huge and growing global market
  • Xanamem™’s innovative, differentiated mechanism of action targeting the stress hormone cortisol
  • Evidence Xanamem™ is both symptomatic and disease modifying
  • Phase II study funded through to completion
  • Patent protected to 2031 – composition of matter
  • Value enhancing additional indications in substantive markets of interest to big pharmaceutical companies – Alzheimers disease, Diabetes, Parkinson’s disease

To view the full announcement, please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now